A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.
| Status: | Completed |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/3/2016 |
| Start Date: | November 2007 |
| End Date: | August 2010 |
Multiple Ascending Dose (MAD) Study of R4733 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
This study will determine the maximum tolerated dose, safety and pharmacokinetic profile of
R4733 (RO4929097), administered orally to patients with refractory metastatic or locally
advanced solid tumors. The study will assess three different dosing schedules; in one
schedule R4733 will be administered 3days on/ 4 days off, in another on days 1-7 of each 21
day cycle, and in a third schedule continuously daily. The starting dose for each dosing
regimen will be escalated in subsequent groups of patients after a satisfactory assessment
of the safety and tolerability of the previous dose. The anticipated time on study treatment
is until disease progression or dose-limiting toxicity, and the target sample size is
100-200 individuals.
R4733 (RO4929097), administered orally to patients with refractory metastatic or locally
advanced solid tumors. The study will assess three different dosing schedules; in one
schedule R4733 will be administered 3days on/ 4 days off, in another on days 1-7 of each 21
day cycle, and in a third schedule continuously daily. The starting dose for each dosing
regimen will be escalated in subsequent groups of patients after a satisfactory assessment
of the safety and tolerability of the previous dose. The anticipated time on study treatment
is until disease progression or dose-limiting toxicity, and the target sample size is
100-200 individuals.
Inclusion Criteria:
- adult patients, >=18 years of age;
- advanced and/or metastatic solid tumor malignancy;
- measurable or evaluable disease;
- ECOG performance status 0 or 1.
Exclusion Criteria:
- prior chemotherapy, radiotherapy or immunotherapy within 28 days of first receipt of
study drug;
- prior corticosteroids as anti-cancer therapy within a minimum of 14 days of first
receipt of study drug. Dexamethasone may be allowed only as part of the supportive
care measures;
- major surgery within 28 days of first receipt of study drug.
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials